Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Grows By 23.8%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the recipient of a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 274,891 shares, a growth of 23.8% from the January 15th total of 222,054 shares. Approximately 4.9% of the shares of the company are sold short. Based on an average daily trading volume, of 41,454 shares, the days-to-cover ratio is presently 6.6 days. Based on an average daily trading volume, of 41,454 shares, the days-to-cover ratio is presently 6.6 days. Approximately 4.9% of the shares of the company are sold short.

Armata Pharmaceuticals Price Performance

Shares of ARMP remained flat at $8.15 during mid-day trading on Tuesday. The stock had a trading volume of 15,606 shares, compared to its average volume of 52,626. Armata Pharmaceuticals has a 1-year low of $0.90 and a 1-year high of $16.34. The stock has a market capitalization of $296.74 million, a price-to-earnings ratio of -5.03 and a beta of 1.42. The business has a fifty day moving average of $6.69 and a 200-day moving average of $5.05.

Institutional Trading of Armata Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. OMERS ADMINISTRATION Corp purchased a new stake in Armata Pharmaceuticals in the fourth quarter valued at approximately $177,000. State Street Corp boosted its holdings in shares of Armata Pharmaceuticals by 26.1% in the 4th quarter. State Street Corp now owns 50,800 shares of the company’s stock valued at $319,000 after purchasing an additional 10,500 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Armata Pharmaceuticals during the 4th quarter valued at $108,000. Renaissance Technologies LLC increased its holdings in shares of Armata Pharmaceuticals by 65.9% during the 4th quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock worth $430,000 after buying an additional 27,200 shares during the last quarter. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Armata Pharmaceuticals in the 4th quarter worth $284,000. 3.57% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, JonesTrading began coverage on shares of Armata Pharmaceuticals in a report on Monday, January 5th. They issued a “buy” rating and a $15.00 target price on the stock. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Armata Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $12.00.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.